If this is the case, it is suspected that a PDGFR-targeted therapy against atherosclerosis and in-stent restenosis may cause a medical complication in hypercholesterolemia or hyperlipidemia patients [40–43]. This evidence concerns the gene PDGFRB and familial hypercholesterolemia.